ZYTOPROTEC AT A GLANCE
Our mission is to make a novel therapeutic approach a reality in PD – an area where clinicians and patients saw disappointingly little innovation in decades.
Zytoprotec, a biomedical company founded in 2007, has consistently moved its lead product – PDprotec® – from basic research through preclinical and clinical development. The product is currently prepared to enter a pivotal Phase III clinical trial in 2022.
The Company is lead by a management team that combines extensive expertise in the renal business, in financing and Venture Capital, as well as in nephrology and clinical development.
MANAGEMENT
- With Zytoprotec since 2015
- Managing Director since November 2015
Prior Experience:
- Joined as Managing Director in November 2015
- Over 20 years experience in the hospital and renal business acting in various management capacities
- In 1997, he sold InfusMedizintechnikas its Managing Director to Baxter
- Occupied several functions within Baxter thereafter, most recently General Manager for Baxter and Gambro-Renal, Austria
- Co-founder of Zytoprotec
- Chief Scientific Officer
Prior Experience:
- Professor of pediatric nephrology and gastroenterology at Medical University of Vienna and Head of division pediatric nephrology and gastroenterology at the department of pediatrics and adolescent medicine
- Has conducted research at Yale and UCLA and teaches medicine at Medical University of Vienna
- Author of more than 100 scientific articles in journals and books and regular speaker at dialysis
- With Zytoprotec since 2014
Prior Experience:
- Over 20 years of expertise in biotech-related venture capital
- Between 1993-2010, general partner and CFO of TVM Capital, a European venture firm
- Managed and structured more than 100 transactions at TVM, including financings, acquisitions and IPOs
Head of Research
Key Milestones
| 2022 | Following promising results of an animal study positive preparation for filing of a new "Indikationspatent" |
| 2022 | Start of a financing round in the form of a public offer of GmbH-shares and atypical silent partnership interests |
| 2022 | Filing of the "double chamber bag patent" in July and positive feedback from the European Patent Office in October (new and inventive) |
| 2021 | Transfer of all silent partnerships from Schilling Group to Auxil |
| 2020-2022 | Preparation of industrial production of PDprotec® |
| 2019/2022 | Letter of Intent with Chinese partner regarding cooperation regarding PDprotec® in China |
| 2019-2022 | Product Development of a five-liter-double-chamber-bag of PDprotec® |
| 2019-2021 | Successful additional financing through convertible loans, silent partnerships and shareholder loans with a total volume of € 5.8 million |
| 2019-2020 | Planning of clinical phase III of PDprotec® in cooperation with Parexel and with positive feedback from the FDA in December 2020 in a so-called pre-IND meeting |
| May 2019 |
Issuance of patent for ICOprotec in China |
| 2019 |
Closing of an EU grant (IMPROVE-PD) with a volume of € 0.5 million |
| 2019 |
Participation in the EU Horizon 2020 project “IMPROVE-PD" |
| 2019 |
Issuance of various awards for team members of our Christian-Doppler-Lab (www.cdg.ac.at) |
| 2018 |
Substantial increase of the scientific adivsory board by adding eight international experts in PD |
| 2017 |
FDA grants PDprotec® Orphan Drug designation
|
| 2017 |
Results of the phase II study on PDprotec®: Excellent data on security and effectiveness
|
| 2016/2017 |
Series A2 Funding
|
| 2016 |
Laboratory for biomarker research in peritoneal dialysis opened by Zytoprotec
|
| 2015 |
Double-blinded, placebo-controlled Phase II study on PDprotec®
|
| 2013 |
Series A Funding
|
| 2012 |
Patent for PDprotec® granted from EPO
|
| 2012 |
Phase I and phase II studies with PDprotec® completed
|
| 2011 |
First financing with private investor
|
| 2007 |
Founding of Zytoprotec
|
|
|
PARTNERS & COOPERATIONS
